Table 2.

Trials evaluating intravenous iron supplementation for treatment of heart failure.

Drug	Authors/ Journal	N	Subjects Studied	Iron Deficiency Definition	Time	Primary Endpoint	Findings
IV Iron Sucrose	Bolger³⁹ JACC 2006	16	NYHA 2–3 LVEF <0.35	Ferritin<400 mg/ml	12 wks	∆ 6MWT	↑ 6MWD, ↓NYHA ↓ MLHF Scores
IV Iron Sucrose	Tobilli²² JACC 2007	40	NYHA 3–4 LVEF<0.35	Ferritin<100ng/ml and/or Tsat<20%	5 wks	∆ Global Assessment score	↑ PGAS, ↑ 6MWD ↓ NT-BNP, ↑ LVEF
IV iron Sucrose	Usmanov⁴⁰ J Nephrol 2008	32	NYHA 3–4 LVEF<0.35	Hb < 11g/dl Iron indices not specified	26 wks	∆ NYHA	↓ NYHA, ↑ LVEF
IV Iron Sucrose	Okonko⁴¹ JACC 2008	35	NYHA 2–3 LVEF<0.35	Ferritin<100 ng/ml or 100–300 with Tsat<20%	16 wks	Δ peak VO₂	↑ PGAS, ↓ NYHA ↑ Peak VO2 α Δ Tsat
IV Iron Carboxy maltose	Anker⁴² NEJM 2009	45	NYHA 2–3 LVEF<0.4 Hb 9.5–13.5	Ferritin<100 ng/ml or 100–300 with Tsat <20%	24 wks	∆ Global Assessment Score	↑ PGAS, ↓NYHA ↑ 6MWD Similar benefit Hb<>12
IV Iron Carboxy maltose	Ponikowski⁴³ EHJ 2014	30	NYHA 2–3 LVEF<0.45 Hb <15	Ferritin<100 ng/ml or 100–300 with Tsat<20%	52 wk	∆ 6MWD	↑ 6MWD ↑ PGAS, ↓NYHA Similar benefit Hb<>12 ↓ HF hospitalization

Tsat, transferrin saturation; 6MWD, 6-minute walk distance; PGAS, patient global assessment score; NT-BNP, N-terminal pro B-type natriuretic peptide; NYHA, New York Heart Association functional class; VO₂, oxygen consumption; Hb, hemoglobin; HF, heart failure.